News for Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics (YMAB) recently experienced a target price adjustment by the investment firm Oppenheimer. Analyst Jeff Jones has maintained an "Outperform"

Oppenheimer has revised its price target for Y-mAbs Therapeutics (YMAB), reducing it from $20 to $15, while maintaining an Outperform rating on the company's st

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in […]

PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the ”œCompany” or ”œY-mAbs”) ( YMAB), a commercial-stage biopharmaceutical

**media[637179]**

On March 31, 2025, Caligan Partners LP (Trades, Portfolio), a New York-based investment firm, expanded its position in Y-mAbs Therapeutics Inc by acquiring an a

H.C. Wainwright has revised its price target for Y-mAbs Therapeutics (YMAB), reducing it to $11 from a previous target of $12. Despite this adjustment, the firm

On May 14, 2025, Truist Securities maintained its "Buy" rating on Y-mAbs Therapeutics (YMAB) while adjusting its price target for the stock. Analyst Nicole Germ

Y-mAbs Therapeutics (YMAB) has retained its

Stock futures are mixed, signaling a potential pause following Monday’s rally driven by optimism over a temporary U.S.-China trade deal. In corporate news, UnitedHealth Group shares plunged 10% after CEO Andrew Witty stepped down, with former CEO Stephen Hemsley stepping in. The company also suspended its outlook due to rising medical costs. Bitcoin has regained value above $103,800, aligning with Coinbase’s rise after inclusion into the S&P 500. In pre-market trading, S&P 500 futures were fla

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Vice President, Head of...

Y-mAbs Therapeutics Inc (YMAB) is set to release its Q1 2025 earnings on May 13, 2025. The consensus estimate for Q1 2025 revenue is $19.61 million, and the ear

Y-mAbs Therapeutics (YMAB) recently shared that the National Comprehensive Cancer Network (NCCN) has endorsed naxitamab-gqgk. This approval is part of the NCCN

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the ”œCompany” or ”œY-mAbs”) ( YMAB), a commercial-stage biopharmaceutical

PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the ”œCompany” or ”œY-mAbs”) ( YMAB), a commercial-stage biopharmaceutical

Y-mAbs Therapeutics (YMAB) will announce its Q1 2025 financial results on May 13, 2025, before the market opens. The company will host a conference call

YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Y-mAbs Therapeutics (YMAB) recently presented groundbreaking preclinical and translational pharmacokinetic data concerning their CD38-SADA compound at the 2025